PMID- 16238676
OWN - NLM
STAT- MEDLINE
DCOM- 20051114
LR  - 20161124
IS  - 0954-6820 (Print)
IS  - 0954-6820 (Linking)
VI  - 258
IP  - 5
DP  - 2005 Nov
TI  - Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 -1612 5A/6A 
      promoter genotype and associated with myocardial infarction.
PG  - 411-9
AB  - OBJECTIVES: Matrix metalloproteinase-3 (MMP-3) is implicated in the formation of 
      atherosclerotic plaques, and the MMP-3 -1612 5A/6A polymorphism is associated 
      with myocardial infarction (MI) and stable coronary artery disease (CAD). The 
      present study examined whether the -1612 5A/6A polymorphism in the promoter 
      region of the MMP-3 gene influences serum concentrations of MMP-3 and whether 
      serum concentrations of MMP-3 are related to extent of coronary atherosclerosis 
      and risk of MI. DESIGN AND SUBJECTS: This case-control study was conducted in 
      three hospitals in the northern part of Stockholm. A total of 755 MI patients 
      aged below 60 were screened, 433 entered and 387 completed the study. Three 
      hundred and eighty-seven sex- and age-matched control subjects were recruited 
      from the general population of the same county. METHODS: The MMP-3 genotype was 
      determined by Pyrosequencing(TM) and the serum MMP-3 concentration was quantified 
      with an immunoassay. Severity and extension of CAD was assessed by quantitative 
      coronary angiography in a subgroup of patients (n=243). RESULTS: Patients had 
      lower serum MMP-3 concentration than controls. There was a strong association 
      between MMP-3 -1612 5A/6A genotype and serum concentrations of MMP-3. The 
      presence of one or two copies of the 6A-allele was associated with a graded 
      increase in serum MMP-3. In female patients there was an inverse correlation 
      (r=-0.39, P<0.05) between serum MMP-3 concentration and plaque area. Conclusion. 
      In conclusion, the serum concentration of MMP-3 is influenced by MMP-3 -1612 
      5A/6A genotype and associated with MI.
FAU - Samnegard, A
AU  - Samnegard A
AD  - Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska 
      Institute, Karolinska University Hospital, Stockholm, Sweden. 
      ann.samnegard@kids.ki.se
FAU - Silveira, A
AU  - Silveira A
FAU - Lundman, P
AU  - Lundman P
FAU - Boquist, S
AU  - Boquist S
FAU - Odeberg, J
AU  - Odeberg J
FAU - Hulthe, J
AU  - Hulthe J
FAU - McPheat, W
AU  - McPheat W
FAU - Tornvall, P
AU  - Tornvall P
FAU - Bergstrand, L
AU  - Bergstrand L
FAU - Ericsson, C-G
AU  - Ericsson CG
FAU - Hamsten, A
AU  - Hamsten A
FAU - Eriksson, P
AU  - Eriksson P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Case-Control Studies
MH  - Coronary Angiography/methods
MH  - Coronary Artery Disease/diagnostic imaging/genetics
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood/genetics
MH  - Middle Aged
MH  - Myocardial Infarction/*genetics
MH  - Phenotype
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Promoter Regions, Genetic/*genetics
MH  - Risk Factors
MH  - Severity of Illness Index
EDAT- 2005/10/22 09:00
MHDA- 2005/11/15 09:00
CRDT- 2005/10/22 09:00
PHST- 2005/10/22 09:00 [pubmed]
PHST- 2005/11/15 09:00 [medline]
PHST- 2005/10/22 09:00 [entrez]
AID - JIM1561 [pii]
AID - 10.1111/j.1365-2796.2005.01561.x [doi]
PST - ppublish
SO  - J Intern Med. 2005 Nov;258(5):411-9. doi: 10.1111/j.1365-2796.2005.01561.x.